Skip to main content
OpenTrials

Clinical trial condition

Metastatic Pancreatic Cancer

Explore clinical trials studying Metastatic Pancreatic Cancer. Study availability and eligibility vary by location and protocol.

134 public trials 27 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Pancreatic Cancer trial results

Active, not recruiting

A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer

NCT06532331

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +6 more
Locations
  • Aichi Cancer Center Nagoya, Aichi-ken, Japan
  • National Cancer Center Hospital East Kashiwa-shi, Chiba, Japan
  • Kanazawa University Hospital Kanazawa, Ishikawa-ken, Japan
  • Kanagawa Cancer Center Yokohama, Kanagawa, Japan
View Trial Details
Active, not recruiting

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

NCT06532344

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +6 more
Locations
  • National Cancer Center Hospital East Kashiwa-shi, Chiba, Japan
  • Kanagawa Cancer Center Yokohama, Kanagawa, Japan
  • Seirei Hamamatsu General Hospital Hamamatsu, Shizuoka, Japan
  • Juntendo University Hospital Bunkyō-Ku, Tokyo, Japan
View Trial Details
Active, not recruiting

Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer

NCT04361162

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +11 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

NCT02077881

Conditions
Adenocarcinoma, Carcinoma, Digestive System Diseases, +15 more
Locations
  • Stanford University Palo Alto, California, United States
  • Augusta University Augusta, Georgia, United States
  • University of Kentucy Lexington, Kentucky, United States
  • Washington University in St. Louis St Louis, Missouri, United States
View Trial Details
Completed

First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI

NCT03693677

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +6 more
Locations
  • Clinique privée de l'Europe Amiens, France
  • CHU Hôtel Dieu Angers, France
  • Hôpital privé Antony, France
  • CH Auxerre, France
View all 36 locations
View Trial Details

Related conditions